Condition: Acromegaly · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Torrance, California, United States | Recruiting |
| Research Site | Aurora, Colorado, United States | Withdrawn |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Ann Arbor, Michigan, United States | Recruiting |
| Research Site | Las Vegas, Nevada, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Portland, Oregon, United States | Recruiting |
| Research Site | CABA, Argentina | Recruiting |
| Research Site | Ciudad de Buenos Aires, Argentina | Recruiting |
| Research Site | Ciudad de Buenos Aires, Argentina | Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07037420